MANNEDORF, SWITZERLAND--(Marketwire - February 13, 2012) - The Tecan Group (SIX: TECN) today announced that the Board of Directors has appointed Dr David
as Chief Executive Officer of the Company. He will join the company as soon
his current contractual obligations permit, but no later than October 8,
As announced on October 7, 2011, the Board of Directors had initiated a
succession process for the top management position. Thomas Bachmann, CEO of
Group since the beginning of 2005, will leave Tecan effective immediately.
Board of Directors has appointed Gérard Vaillant as acting Chief
Officer until David Martyr joins the company. Gérard Vaillant has been
of the Tecan Board of Directors since 2004.
David Martyr joins Tecan with an extensive management career in technology
businesses, including 13 years of leadership experience in the life
sector and analytical instrument industry. Most recently, David Martyr was
President of Leica Microsystems since 2007 and concurrently Vice President
Danaher Corporation, with responsibility for Danaher's Life Science
since 2009. During the period 2007 to 2011 at Leica Microsystems, the
business grew from around USD 500 million annual sales to over USD 1.2
through driving organic growth, the introduction of reagents and
complement its instruments, significantly expanding sales in China; and
the acquisition and integration of several companies.
"David Martyr has extensive leadership experience in the life sciences
and a successful track record in improving the performance of his
well as growing new business opportunities," said Rolf Classon, Chairman of
Tecan's Board of Directors. "David has extensive knowledge and experience
sales, marketing and business development within the life sciences sector
are convinced that under his leadership Tecan will continue to generate
accelerated profitable growth."
"Tecan is the premier brand in laboratory automation and I am excited to
the Company at a time when automation is gaining widespread adoption in the
Sciences and Clinical Diagnostics," said David Martyr. "Together with the
management team, I look forward to continue to implement Tecan's successful
growth strategy in both the Life Sciences Business and the Partnering
segments and to further build value for our shareholders."
Rolf Classon continued: "During the tenure of Thomas Bachmann, Tecan has
improved operational effectiveness, improved earnings per share and built a
strong balance sheet. We will continue to build on this solid foundation
will ensure continuity, also under the new leadership. The Board thanks
Bachmann for his important accomplishments and strong commitment and we
the very best going forward."
Additional information on David Martyr
David Martyr joined Leica Microsystems in 1998 and was appointed President
Leica Microsystems Group in January 2007 with full responsibility for Leica
Microsystems, Leica Biosystems and Invetech.
Leica Microsystems Group, with over 4000 employees in 20 countries, is a
player in Life Science instrumentation, Microscopy, Cancer Diagnostics
(instruments and reagents), Medical Technologies and advanced imaging
for industrial and forensic applications.
Since January 2009 David Martyr concurrently served as Group Executive and
President of Danaher Corporation (NYSE: DHR), the shareholder of Leica
Microsystems Group. In this role he was responsible for overseeing the
development of Danaher's Life Science businesses, which today also include
spectrometry company AB Sciex and Molecular Devices focused on detection
Prior to being appointed as President, David Martyr held various management
professional positions at Leica Microsystems, including Executive Vice
Worldwide Sales and Marketing and Managing Director, Europe.
Prior to joining Leica Microsystems David Martyr worked for laser
companies Lumonics Inc. and Ferranti plc in a variety of management and
David Martyr holds a B.Sc. in Naval Architecture and earned a doctorate in
Engineering at the University of Newcastle-upon-Tyne, United Kingdom. He is
years old and a British citizen.
A photo of Dr David Martyr can be requested at email@example.com
Tecan (www.tecan.com) is a leading global provider of laboratory
solutions in biopharmaceuticals, forensics and clinical diagnostics. The
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its
include pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales
service network in 52 countries. In 2010, Tecan generated sales of
CHF 371 million (USD 356 million; EUR 269 million). Registered shares of
Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE